Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCOTCMKTS:EMISNASDAQ:MRUSNASDAQ:STSANASDAQ:XENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/AEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AMRUSMerus$41.17+1.8%$45.05$18.21▼$52.03$2.42B1.1569,565 shs296,990 shsSTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shsXENEXenon Pharmaceuticals$41.18+2.9%$44.61$27.99▼$50.99$3.11B1.15399,209 shs125,370 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%MRUSMerus+1.61%-1.99%-11.93%+16.87%+83.86%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+5.77%XENEXenon Pharmaceuticals+0.33%-3.15%-9.07%-11.19%+1.57%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus3.0613 of 5 stars4.53.00.00.02.91.70.0STSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals1.6808 of 5 stars3.52.00.00.02.12.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AMRUSMerus3.00Buy$56.3336.83% UpsideSTSASatsuma PharmaceuticalsN/AN/AN/AN/AXENEXenon Pharmaceuticals3.00Buy$59.4444.35% UpsideCurrent Analyst RatingsLatest MRUS, BSTC, EMIS, XENE, and STSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/12/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$62.004/11/2024MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.004/10/2024XENEXenon PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.003/28/2024MRUSMerusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$69.003/4/2024MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$42.00 ➝ $65.003/1/2024XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.003/1/2024XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.003/1/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $62.002/29/2024MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $65.002/29/2024MRUSMerusStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $65.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AMRUSMerus$43.95M54.98N/AN/A$6.17 per share6.67STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AXENEXenon Pharmaceuticals$9.43M329.40N/AN/A$14.18 per share2.90Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/AEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AMRUSMerus-$154.94M-$3.04N/AN/AN/A-352.56%-50.61%-37.56%5/2/2024 (Estimated)STSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/AXENEXenon Pharmaceuticals-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)Latest MRUS, BSTC, EMIS, XENE, and STSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023XENEXenon Pharmaceuticals-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A 2/28/2024Q4 2023MRUSMerus-$0.71-$1.09-$0.38-$1.09$10.43 million$8.94 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24EMISEmisphere TechnologiesN/AN/AN/AMRUSMerusN/A5.345.34STSASatsuma PharmaceuticalsN/A7.447.44XENEXenon PharmaceuticalsN/A23.6523.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%EMISEmisphere TechnologiesN/AMRUSMerus96.14%STSASatsuma Pharmaceuticals93.26%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%EMISEmisphere Technologies72.90%MRUSMerus4.30%STSASatsuma Pharmaceuticals31.20%XENEXenon Pharmaceuticals5.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableEMISEmisphere Technologies6N/AN/ANot OptionableMRUSMerus17258.69 million56.16 millionOptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableXENEXenon Pharmaceuticals25175.43 million71.34 millionOptionableMRUS, BSTC, EMIS, XENE, and STSA HeadlinesSourceHeadlineFederated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 23 at 5:35 AMInvestors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)americanbankingnews.com - April 18 at 3:04 AMXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 16 at 8:30 AMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analystsamericanbankingnews.com - April 16 at 2:34 AMXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - April 14 at 3:36 AMNeedham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)marketbeat.com - April 12 at 8:14 AMXenon Pharmaceuticals Inc (XENE)investing.com - April 10 at 12:10 PMXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferenceglobenewswire.com - April 10 at 8:30 AMXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 4:01 PMSG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 2 at 4:18 AMAssenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)marketbeat.com - April 1 at 4:43 AMXenon Pharmaceuticals Incmoney.usnews.com - March 21 at 10:13 AMXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - March 19 at 8:26 AMXENE Apr 2024 47.500 putfinance.yahoo.com - March 16 at 1:48 PMXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 12 at 4:01 PMInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stockinsidertrades.com - March 11 at 6:41 AMInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...finance.yahoo.com - March 9 at 12:06 AMXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 5 at 4:01 PMBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progressmarkets.businessinsider.com - March 5 at 10:33 AMXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 2 at 2:52 PMXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:52 AMXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 1 at 2:30 PMXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focuszacks.com - March 1 at 9:36 AMBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neurosciencemarkets.businessinsider.com - March 1 at 9:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.MerusNASDAQ:MRUSMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Xenon PharmaceuticalsNASDAQ:XENEXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.